AMERICAN BIOGENETIC SCIENCES, FIBRINOGEN ANTIBODY PATENT ALLOWED
AMERICAN BIOGENETIC SCIENCES, FIBRINOGEN ANTIBODY PATIENT ALLOWED
NOTRE DAME, Ind., Nov. 12 /PRNewswire/ -- American Biogenetic Sciences, Inc. (NASDAQ: MABXA) announced today that it has received notice from the United States Patent and Trademark Office allowing its monoclonal antibody 45J patent application.
The 45J monoclonal antibody is utilized in the company's first commercial product, "Cadkit," a manual test that measures levels of fibrinogen in blood plasma. Fibrinogen is gaining increasing recognition as a major independent risk factor for cardiovascular disease. Several population-based studies have found that elevated levels of fibrinogen eclipse cholesterol as a predictor of future cardiovascular events such as heart attacks and strokes.
Based on 100 million cholesterol tests administered annually in the United States, ABS president, Henry L. Nordhoff, estimates the potential worldwide annual market for a fibrinogen test at about $400 million. The market potential is expected to include its use during routine physical examinations in men over 35 and in post-menopausal women. The possibility of using the test to monitor fibrinogen levels during clot dissolving therapy is also being investigated.
The Cadkit, which received U.S. Food and Drug Administration clearance of a 510(k) application earlier this year, is a manual latex agglutination test that directly measures fibrinogen levels by utilizing the 45J monoclonal antibody, which is highly specific for fibrinogen. The Cadkit was recently introduced in Europe. ABS is discussing U.S. marketing rights to an automated version of Cadkit with a number of major pharmaceutical companies.
American Biogenetic Sciences, Inc. is a biopharmaceutical company that conducts research and development at The University of Notre Dame in Notre Dame, Ind., and Trinity College, Dublin, Ireland. Its primary corporate objective is to commercialize monoclonal antibody-based products which diagnose, prevent and treat cardiovascular disease. The monoclonal antibodies are generated from the company's unique antigen- free mouse colony. ABS is also developing recombinant vaccine for major diseases currently lacking effective vaccine protection.
/CONTACT: Maureen Murray of American Biogenetic Sciences, Inc., 516-789-2600; Anthony J. Russo or Bonnie Sterling of Noonan/Russo Communications, 212-979-9180/
(MABXA) CO: American Biogenetics Sciences, Inc. ST: Indiana IN: MTC SU: PDT SM-KW -- NY068 -- 3538 11/12/91 14:53 EST